Trials / Completed
CompletedNCT01247168
An Open-Label, Dose-Escalation Study of AZD2461
An Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics fo the PARP Inhibitor AZD2461 in Patients With Refractory Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to test study drug AZD2461 to see how it may work to treat solid tumors. The main purpose of this study is to determine the safety and tolerability of AZD2461. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2461 | oral capsules, continuous dosing and intermittent dosing |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2010-11-24
- Last updated
- 2012-06-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01247168. Inclusion in this directory is not an endorsement.